Pathwork Diagnostics, Novartis partnership
This article was originally published in The Gray Sheet
Pathwork Diagnostics will work with Novartis to discover "clinically meaningful biomarker signatures" that can be used to develop diagnostics for a variety of cancers. Financial terms were not disclosed, but the deal gives both parties the rights to develop and commercialize diagnostic products developed from their partnership. Pathwork is based in Redwood City, Calif
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.